Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Supraflex Stent Implantation

PHASE4RecruitingINTERVENTIONAL
Enrollment

3,010

Participants

Timeline

Start Date

December 18, 2023

Primary Completion Date

September 30, 2026

Study Completion Date

December 31, 2026

Conditions
Percutaneous Coronary Intervention (PCI)Atrial Fibrillation (AF)Oral AnticoagulationP2Y12 Inhibitor
Interventions
DRUG

P2Y12 inhibitor

The choice of P2Y12 inhibitor is left at investigator's discretion.

DRUG

Aspirin

Aspirin is administered for up to 1 month after PCI at investigator's discretion

DRUG

DOAC

The choice of DOAC is left at investigator's discretion.

Trial Locations (15)

1081

NOT_YET_RECRUITING

UMC public, Amsterdam

1211

RECRUITING

Hôpitaux Universitaires de Genève, Geneva

3010

RECRUITING

Inselspital, Bern University Hospital, Department of Cardiology, Bern

3500

NOT_YET_RECRUITING

Hartcentrum Hasselt, Hasselt

4031

RECRUITING

Universitätsspital Basel, Basel

6900

RECRUITING

Cardiocentro Ticino Institute, Lugano

8091

RECRUITING

University Hospital Zürich, Zurich

20089

NOT_YET_RECRUITING

IRCCS Humanitas, Milan

30029

NOT_YET_RECRUITING

CHU Nîmes, Nîmes

39008

NOT_YET_RECRUITING

Hospital Universitario Marques de Valdecilla, Santander

60590

NOT_YET_RECRUITING

Universitätsklinikum Frankfurt/Main, Frankfurt am Main

88048

NOT_YET_RECRUITING

Klinikum Friedrichshafen, Friedrichshafen

95124

NOT_YET_RECRUITING

Ospedale Ferrarotto, Catania

61-701

NOT_YET_RECRUITING

Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, Poznan

SW7 2AZ

NOT_YET_RECRUITING

Imperial College London, London

All Listed Sponsors
collaborator

Sahajanand Medical Technologies Limited

INDUSTRY

lead

Insel Gruppe AG, University Hospital Bern

OTHER